Compound: Vildagliptin
SMILES: O=C(N1[C@H](C#N)CCC1)CNC23CC4(O)CC(C2)CC(C3)C4
InChIKey: SYOKIDBDQMKNDQ-XWTIBIIYSA-N
Synonyms: Vildagliptin, Galvus, 274901-16-5, NVP-LAF237, Equa, LAF237, LAF-237, Vitagliptin, NVP-LAF 237, (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile, vildagliptine, Vildagliptina, I6B4B2U96P, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, DTXSID80881091, vildagliptinum, NVP LAF237, (2S)-{((3-Hydroxyadamantan-1-yl)amino)acetyl}pyrrolidine-2-carbonitrile, (2S)-1-(2-((3-hydroxy-1-adamantyl)amino)acetyl)pyrrolidine-2-carbonitrile, RefChem:6349, DTXCID501508682, Xiliarx, Jalra, Vildagliptin (LAF-237), LAF 237, NVP-LAF-237, 2-Pyrrolidinecarbonitrile, 1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-, CHEMBL142703, (2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile, 2-Pyrrolidinecarbonitrile, 1-(((3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)amino)acetyl)-, (2S)-, Galvus (TN), Vidagliptin (see Vildagliptin), Vildagliptin [USAN], UNII-I6B4B2U96P, Zomelis, 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile, Vildagliptin (JAN/USAN/INN), Zomelis;, Galvus;, (S)-1-(2-(((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, Vildagliptin [USAN:INN:BAN:JAN], Equa (TN), VILDAGLIPTIN [MI], VILDAGLIPTIN [INN], VILDAGLIPTIN [JAN], SCHEMBL16579, VILDAGLIPTIN [MART.], VILDAGLIPTIN [WHO-DD], GTPL6310, VILDAGLIPTIN [EMA EPAR], BDBM11695, Vildagliptin - Bio-X trade mark, A10BD08, A10BH02, CHEBI:135285, SYOKIDBDQMKNDQ-XWTIBIIYSA-N, MSK11066, s3033, AKOS015898120, AC-1273, CCG-267505, CS-1465, DB04876, FV29102, NCGC00386200-01, NCGC00386200-02, BV164521, HY-14291, NS00010516, SW220049-1, D07080, AB01566863_01, EN300-18527744, Q421042, BRD-A94993966-001-04-4, BRD-A94993966-001-05-1, (2S)-1-[N-(3-Hydroxyadamantan-1-yl)glycyl]pyrrolidine-2-carbonitrile, (2S)-1-{[(3-hydroxyadamant-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile, (2S)-1-{2-[(3-Hydroxyadamant-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile, (2S)-1-{[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile, 1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile, (-)-(2S)-1-(((3-HYDROXYTRICYCLO(3.3.1.1(SUP(3,7))DEC-1-YL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE, (2S)-1-(((3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE, 2-PYRROLIDINECARBONITRILE, 1-(((3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)AMINO)ACETYL)-, (2S)-, 2S)-1-[[(3-Hydroxytricyclo[3.3.1.13,7]decane-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile
Theoretical properties:
molecular_formula: C17H25N3O2
molecular_weight: 303.4 g/mol
exact_mass: 303.19467705 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 22
topological_polar_surface_area: 76.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 1.75e+00 g/L
Descriptions:
pubchem: Vildagliptin is an amino acid amide.
chembl: VILDAGLIPTIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
The most common side effects include dizziness.
It was approved by the European Medicines Agency (EMA) in 2007. The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.